Our lead candidate - Visomitin - contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.
Why is ROS scavenging in mitochondria important?
The accumulation of Visomitin in the mitochondrial membrane disrupts the chain reaction of lipid degeneration. Mitochondrial ROS (mtROS) have been shown to cause damage to the mitochondrial membrane leading to mitochondrial dysfunction and apoptosis. mtROS have also been linked to uncontrolled progression of inflammation. Growing evidence additionally suggests that mtROS significantly contributes to the aging process - oxidative stress-mediated mitochondrial dysfunction is considered one of the contributors to aging.
Visomitin and the challenge of drug development
Development of effective delivery methods for mitochondria-targeted antioxidants has historically been a challenging task. We have successfully solved this complex problem and have designed several pharmaceutical products currently going through various stages of clinical development: from pre-clinical to late-stage clinical. We have also conducted a large volume of safety studies in pre-clinical and clinical programs in the U.S. and demonstrated excellent safety and tolerability profile for Visomitin.
We at Mitotech are determined to keep expanding our pipeline in order to aid millions of patients worldwide with unmanaged ophthalmic disorders.